Remoxipride is an discontinued atypical antipsychotic selective for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.
- Mechanism
- Curator reviewed · 6 references
Remoxipride is an atypical antipsychotic dopamine D2 antagonist. Chronic use upregulates the expression of D2 receptors, while downregulating the expression of D1 and D5 receptors in the prefrontal cortex. This activity may be related to the antipsychotic activity of remoxipride. Remoxipride displays weaker binding to D2 dopaminergic receptors that dopamine. This weaker binding is thought to account for the reduced incidence of Parkinsonism. Remoxipride also increases expression of the protein Fos in the nucleus accumbens but not the dorsolateral striatum, which may be responsible for a reduced incidence of extrapyramidal symptoms.
- Primary indication
- Remoxipride is an atypical antipsychotic once used for the treatment of schizophrenia.Curator reviewed
- Formula / weight
- C16H23BrN2O3 · 371.269 g/mol (avg)
- Code names
- A-33547 · FLA-731(-)
Resolves to
GUJRSXAPGDDABA-NSHDSACASA-NSMILESCCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OCWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Remoxipride, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account